The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign ...

This maker of weight-loss drugs saw its share price zoom and then crash. The CEO has been replaced. The incoming boss will ...

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Novo Nordisk A/S (NYSE:NVO) is one of the top 10 medical AI companies to buy according to analysts. On July 29, Novo Nordisk ...

Management told investors to expect slower sales and profit growth in 2025.

Denmark’s status as one of the few countries in Europe with an expanding economy rests in part on the success of its homegrown hero, Novo Nordisk A/S. Thanks to the pharmaceutical giant’s astronomical ...

In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ...

A larger thymus size at 2 months of age is linked to an increased likelihood of having atopic dermatitis within the first 2 ...

Youth ages 1 to 18 consumed more calories from UPFs than adults: 61.9% of calories consumed versus 53% for adults.

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...